Title : Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance - Wang_2020_Eur.J.Med.Chem__112915 |
Author(s) : Wang L , Bharti , Kumar R , Pavlov PF , Winblad B |
Ref : Eur Journal of Medicinal Chemistry , :112915 , 2020 |
Abstract :
Alzheimer's disease (AD) is the most common form of dementia characterized by presence of extracellular amyloid plaques and intracellular neurofibrillary tangles composed of tau protein. Currently there are close to 50 million people living with dementia and this figure is expected to increase to 75 million by 2030 putting a huge burden on the economy due to the health care cost. Considering the effects on quality of life of patients and the increasing burden on the economy, there is an enormous need of new disease modifying therapies to tackle this disease. The current therapies are dominated by only symptomatic treatments including cholinesterase inhibitors and N-methyl-D-aspartate receptor blockers but no disease modifying treatments exist so far. After several failed attempts to develop drugs against amyloidopathy, tau targeting approaches have been in the main focus of drug development against AD. After an overview of the tauopathy in AD, this review summarizes recent findings on the development of small molecules as therapeutics targeting tau modification, aggregation, and degradation, and tau-oriented multi-target directed ligands. Overall, this work aims to provide a comprehensive and critical overview of small molecules which are being explored as a lead candidate for discovering drugs against tauopathy in AD. |
PubMedSearch : Wang_2020_Eur.J.Med.Chem__112915 |
PubMedID: 33139110 |
Wang L, Bharti, Kumar R, Pavlov PF, Winblad B (2020)
Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance
Eur Journal of Medicinal Chemistry
:112915
Wang L, Bharti, Kumar R, Pavlov PF, Winblad B (2020)
Eur Journal of Medicinal Chemistry
:112915